Last update 08 May 2025

QLS5132

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Target
CLDN6 x Top I
Action
inhibitors
Mechanism
CLDN6 inhibitors(Claudin 6 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseRespiratory Diseases+ [1]
Active Indication
Advanced Malignant Solid NeoplasmEndometrial CarcinomaNon-Small Cell Lung Cancer+ [2]
Inactive Indication-
Originator Organization
Qilu Pharmaceutical Co., Ltd.Qilu Pharmaceutical Co., Ltd.
Active Organization
Qilu Pharmaceutical Co., Ltd.Qilu Pharmaceutical Co., Ltd.Qilu Pharmaceuticals Co. Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with QLS5132
NCT06932094
/ Not yet recruitingPhase 1
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of QLS5132 Monotherapy in Subjects With Advanced Solid Tumors
100 Clinical Results associated with QLS5132
Login to view more data
100 Translational Medicine associated with QLS5132
Login to view more data
100 Patents (Medical) associated with QLS5132
Login to view more data
100 Deals associated with QLS5132
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
China
Qilu Pharmaceutical Co., Ltd.Qilu Pharmaceutical Co., Ltd.
01 May 2025
Endometrial CarcinomaPreclinical
China
Qilu Pharmaceuticals Co. Ltd.
30 Apr 2025
Non-Small Cell Lung CancerPreclinical
China
Qilu Pharmaceuticals Co. Ltd.
30 Apr 2025
Ovarian CancerPreclinical
China
Qilu Pharmaceuticals Co. Ltd.
30 Apr 2025
Testicular NeoplasmsPreclinical
China
Qilu Pharmaceuticals Co. Ltd.
30 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free